An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate

Documenti analoghi

• Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration’s Approval of Oncology Drugs
  di: Kim, Chul, et al.
  Pubblicazione: (2016)
• FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
  di: Chen, Emerson Y., et al.
  Pubblicazione: (2020)
• Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
  di: Hilal, Talal, et al.
  Pubblicazione: (2020)
• Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018
  di: DeMartino, Patrick C., et al.
  Pubblicazione: (2020)
• Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
  di: Hilal, Talal, et al.
  Pubblicazione: (2019)